Literature DB >> 15995479

Escharotomy using an enzymatic debridement agent for treating experimental burn-induced compartment syndrome in an animal model.

Yuval Krieger1, Lior Rosenberg, Oren Lapid, Ronen Glesinger, Alex Bogdanov-Berezovsky, Eldad Silberstein, Amiram Sagi, Keith Judkins.   

Abstract

BACKGROUND: In patients with deep circumferential burns, adequate resolution of burn-induced compartment syndrome (BICS) is achieved by surgical escharotomy. Surgical escharotomy is traumatic, may cause considerable blood loss, does nothing toward debridement of the burn wound, and entails possible morbidity and complications. Debridase is a Bromelain derived enzymatic preparation capable of lysing the burn eschar within 4 hours, obviating the need for surgical debridement. It has an affinity to burned necrotic tissue and does not damage healthy skin. In our clinical assessment of the Debridase efficacy, we found in several cases of deep burns of the limbs that the measured IC pressure subsided after 2-4 hours of Debridase application and none of the enzymatic escharotomy treated patients suffering from circumferential burns developed BICS. To confirm these observations we conducted this controlled study. AIM: to assess the efficacy of Debridase for treating BICS in an animal model.
MATERIALS AND METHODS: A model for BICS was developed by making circumferential burns to pig legs and monitoring the anterior compartment the legs. BICS was induced in the legs of 5 pigs, 20 legs. 10 legs were treated with Debridase and 10 served as nontreated controls, treated by surgical escharotomy at the conclusion of the experiment.
RESULTS: Debridase reduced BICS within 30 minutes from application. Debridase was as effective as a standard surgical escharotomy.
CONCLUSION: Escharectomy using an effective enzymatic debriding agent is potentially an adequate, simple, fast and effective procedure to treat BICS, it has the added benefit of burn debridement without surgical escharotomy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995479     DOI: 10.1097/01.ta.0000169867.08607.f1

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  11 in total

1.  Minimally invasive burn care: a review of seven clinical studies of rapid and selective debridement using a bromelain-based debriding enzyme (Nexobrid®).

Authors:  L Rosenberg; Y Shoham; Y Krieger; G Rubin; F Sander; J Koller; K David; D Egosi; R Ahuja; A J Singer
Journal:  Ann Burns Fire Disasters       Date:  2015-12-31

2.  Bromelain-based enzymatic debridement and minimal invasive modality (mim) care of deeply burned hands.

Authors:  Y Krieger; G Rubin; A Schulz; N Rosenberg; A Levi; A J Singer; L Rosenberg; Y Shoham
Journal:  Ann Burns Fire Disasters       Date:  2017-09-30

3.  Delayed and fractional use of enzymatic debridement with nexobrid for extensive burn injury: a case report.

Authors:  S Krauss; D Bender; J Rothenberger; J Daigeler; M Held
Journal:  Ann Burns Fire Disasters       Date:  2018-03-31

4.  Rapid enzymatic burn debridement: A review of the paediatric clinical trial experience.

Authors:  Yaron Shoham; Yuval Krieger; Guy Rubin; Ingo Koenigs; Bernd Hartmann; Frank Sander; Alexandra Schulz; Keren David; Lior Rosenberg; Eldad Silberstein
Journal:  Int Wound J       Date:  2020-05-22       Impact factor: 3.315

5.  The entity of thermal-crush-avulsion hand injury (hot-press roller burns) treated with fast acting debriding enzymes (nexobrid): literature review and report of first case.

Authors:  A Di Castri; L Quarta; I Mataro; F Riccardi; G Pezone; L Giordano; Y Shoham; L Rosenberg; E Caleffi
Journal:  Ann Burns Fire Disasters       Date:  2018-03-31

6.  Bromelain-based enzymatic debridement of chronic wounds: A preliminary report.

Authors:  Yaron Shoham; Yuval Krieger; Eran Tamir; Eldad Silberstein; Alexander Bogdanov-Berezovsky; Josef Haik; Lior Rosenberg
Journal:  Int Wound J       Date:  2018-04-25       Impact factor: 3.315

7.  A new bromelain-based enzyme for the release of Dupuytren's contracture: Dupuytren's enzymatic bromelain-based release.

Authors:  G Rubin; M Rinott; A Wolovelsky; L Rosenberg; Y Shoham; N Rozen
Journal:  Bone Joint Res       Date:  2016-05       Impact factor: 5.853

8.  Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds.

Authors:  Giuseppe Giudice; Angela Filoni; Giulio Maggio; Domenico Bonamonte; Michelangelo Vestita
Journal:  Biomed Res Int       Date:  2017-02-15       Impact factor: 3.411

9.  Effects of topical Kiwifruit on healing of neuropathic diabetic foot ulcer.

Authors:  Gholamreza Mohajeri; Masumeh Safaee; Mohamad Hossein Sanei
Journal:  J Res Med Sci       Date:  2014-06       Impact factor: 1.852

10.  A Questionnaire-Based Study to Obtain a Consensus from 5 Polish Burns Centers on Eschar Removal by Bromelain-Based Enzymatic Debridement (Nexobrid®) in Burns Following the 2020 Updated European Consensus Guidelines.

Authors:  Tomasz Korzeniowski; Jerzy Strużyna; Anna M Chrapusta; Andrzej Krajewski; Marek Kucharzewski; Krzysztof Piorun; Jakub Nowakowski; Agnieszka Surowiecka; Magdalena Kozicka; Kamil Torres
Journal:  Med Sci Monit       Date:  2022-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.